An intelligent therapy conceived in Italy has been approved by Aifa with a double indication: against lung cancer but also "broad spectrum" for various other cancers
.
It is the first time that a therapy is born with this type of indication, so much so that a new concept has been introduced: that of an agnostic target, that is, it acts independently of the organ affected by the tumor.
Treatment has been shown to be effective in patients with different types of solid tumors, including sarcoma, non-small cell lung cancer, mammary analogue secretory carcinoma of the salivary glands, secretory and non-secretory breast cancer, thyroid cancer, colorectal, neuroendocrine, pancreatic, ovarian carcinoma, endometrial carcinoma, cholangiocarcinoma, gastrointestinal tumors and neuroblastoma including lung, colon, neuroblastoma and many other solid tumors. Patients who have a particular mutation, the NTRK, identified with a test, will be able to access it.
Entrectinib is a molecularly targeted drug whose creation started from studies in the laboratories of Nerviano Medical Sciences and continued the subsequent phases at the Niguarda Cancer Center and at the National Cancer Institute in Milan.
AIFA's go-ahead reads in a note from Roche "marks a revolutionary turning point in the panorama of precision oncology and in the national regulatory context". "We are doubly proud of this goal, achieved thanks to scientific research made in Italy and a cutting-edge regulatory process, which, compared to other countries, has made it possible for Italian patients to access intelligent personalized therapy" said Maurizio. de Cicco, President and CEO of Roche Italia. Philip de Braud,Full Professor of Oncology at the University of Milan and Director of the Department of Medical Oncology and Hematology Fondazione IRCCS Istituto Nazionale Tumori di Milano explained that the value of this target therapy is amply demonstrated by the evidence collected in clinical trials and good response rates are obtained. intracranial, greater than 50%, in the presence of brain metastases at baseline. This therapy can truly revolutionize treatment prospects for "ROS1-positive advanced non-small cell lung cancer patients and for patients with NTRK-positive tumors. Its marked efficacy allows it to be system-wide active. central nervous system, often the site of metastases that are difficult to treat,offering cancer patients new treatment options and improved life expectancy - said Silvia Novello, Full Professor of Medical Oncology at the University of Turin and President of WALCE Onlus (Women Against Lung Cancer in Europe) . - Clinical trials show a response in about 70% of patients with ROS1-positive NSCLC lung cancer of which 35% had brain metastases, also highlighting a good profile of tolerability and handling, fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ". Professor of Medical Oncology at the University of Turin and President of WALCE Onlus (Women Against Lung Cancer in Europe). - Clinical trials show a response in about 70% of patients with ROS1-positive NSCLC lung cancer of which 35% had brain metastases, also highlighting a good profile of tolerability and handling, fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".Professor of Medical Oncology at the University of Turin and President of WALCE Onlus (Women Against Lung Cancer in Europe). - Clinical trials show a response in about 70% of patients with ROS1-positive NSCLC lung cancer of which 35% had brain metastases, also highlighting a good profile of tolerability and handling, fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".- Clinical trials show a response in about 70% of patients with ROS1-positive NSCLC lung cancer of which 35% had brain metastases, also highlighting a good profile of tolerability and handling, fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".- Clinical trials show a response in about 70% of patients with ROS1-positive NSCLC lung cancer of which 35% had brain metastases, also highlighting a good profile of tolerability and handling, fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".fundamental aspects for both clinicians and patients who can benefit from this oral therapy. For the correct and profitable use of this, as well as of the other targeted drugs, it is essential to identify the action targets, carrying out genomic profiling tests that identify the genetic alterations ".
